Clinical trial · Interventional
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
a Study of Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
NCT07117890CI-TRIAL-00099639WU-KONG35recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sunvozertinib 200mg | Drug | Sunvozertinib | ALIAS |
| sunvozertinib 300mg | Drug | Sunvozertinib | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Sunvozertinib 300mg
- description
- sunvozertinib monotherapy, 300mg QD
- interventionNames
- Drug: sunvozertinib 300mg
- type
- EXPERIMENTAL
- label
- sunvozertinib 200mg
- description
- sunvozertinib monotherapy, 200mg QD
- interventionNames
- Drug: sunvozertinib 200mg
Primary outcomes (1)
- measure
- Objective Response Rate(ORR)
- timeFrame
- from first dose to last dose ,up to 24 months
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. ≥18 years old 2. histologically or cytologically confirmed non-squamous NSCLC with documented EGFR uncommon mutations from a local laoratory. at least one EGFR uncommon mutation (excluding EGFR 19del/l858r/T790m/Ex 20ins ) or compund mutations with EGFR uncommon mutations. 3. predicted life expectancy ≥ 12 weeks. 4. patient must have measurable disease according to RECIST 1.1 Exclusion Criteria: 1. previos systemic anti-tumor therapy 2. a history of malignant tumors within 2years 3. any severa or poorly controlled systemic disease per investigator's judgement 4. active infections
References
Publications (0)
Data not yet available
No reference posted for this study.